Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 492-497 , December 2009

A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract

  • Xuejun Ma

      Affiliations

    • Department of Radiation Oncology
    • Contributed equally to this study.
    • ,
  • Ye Guo

      Affiliations

    • Department of Medical Oncology
    • Contributed equally to this study.
    • ,
  • Ziqiang Pang

      Affiliations

    • Department of Radiation Oncology
    • ,
  • Biyun Wang

      Affiliations

    • Department of Medical Oncology
    • ,
  • Hongfen Lu

      Affiliations

    • Department of Pathology; and
    • ,
  • Ya-Jia Gu

      Affiliations

    • Department of Radiology, Fudan University, Shanghai, China
    • ,
  • Xiaomao Guo

      Affiliations

    • Department of Radiation Oncology
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, Cancer Hospital of Fudan University, Shanghai Medical College, Fudan University, 270 Dong An Road, Shanghai 200032, China.

Received 31 March 2009 ,Revised 15 August 2009 ,Accepted 30 August 2009.

References 

  1. Chan JKC JE, Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues.. Lyon, France: IARC Press; 2001;p. 204–207
  2. Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer. 1998;83:806–812
  3. Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16:206–214
  4. Kim TM, Lee SY, Jeon YK, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol. 2008;19:1477–1484
  5. Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005;41:1402–1408
  6. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103:216–221
  7. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–26
  8. Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197–1205
  9. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24:181–189
  10. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54:182–190
  11. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006
  12. Messori A, Vaiani M, Trippoli S, Rigacci L, Jerkeman M, Longo G. Survival in patients with intermediate or high grade non-Hodgkin’s lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer. 2001;84:303–307
  13. Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008;70:166–174
  14. Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?. Ann Oncol. 2001;12:349–352
  15. Lee J, Kim WS, Park YH, et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer. 2005;92:1226–1230
  16. Stolinsky DC, Solomon J, Weiner JM, Bateman JR. Results with CCNU in resistant Hodgkin’s and non-Hodgkin’s lymphoma. Oncology. 1976;33:271–273
  17. Maurice P, Glidewell O, Jacquillat C, et al. Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin’s disease, lymphosarcoma nad reticulum cell sarcoma. Cancer. 1978;41:1658–1663
  18. Sweetenham JW, McKendrick JJ, Mead GM, Whitehouse JM. Prednisolone, cytosine arabinoside, lomustine (CCNU), etoposide and thioguanine (PACET) combination chemotherapy for relapsed or refractory non-Hodgkin lymphoma. Eur J Cancer. 1993;29A:190–192
  19. Musolino A, Perrone MA, Michiara M, et al. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. Cancer. 2005;103:2109–2117
  20. Guo Y, Lu JJ, Ma X, et al. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Oral Oncol. 2008;44:23–30
  21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol. 1999;17:1244
  22. Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than international prognostic index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106:3785–3790
  23. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22:3032–3038
  24. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood. 1993;81:2215–2222
  25. Kobayashi Y, Yamashiro T, Nagatake H, et al. Expression and function of multidrug resistance P-glycoprotein in a cultured natural killer cell-rich population revealed by MRK16 monoclonal antibody and AHC-52. Biochem Pharmacol. 1994;48:1641–1646
  26. Drenou B, Lamy T, Amiot L, et al.  CD3- CD56+ non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance. Blood. 1997;89:2966–2974
  27. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999;93:599–606
  28. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351–2356
  29. Jung CK, Lee KY, Kim Y, et al. Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas. Pathol Int. 2001;51:355–3563
  30. Kim GE, Yang WI, Lee SW, et al. Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. Leuk Lymphoma. 2004;45:1857–1864
  31. Wang B, Li XQ, Ma X, Hong X, Lu H, Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 2008;83:795–799
  32. Lee KW, Yun T, Kim DW, et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/− radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma. 2006;47:1274–1282
  33. Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol. 2002;20:197–1204
  34. Shikama N, Izuno I, Oguchi M, et al. Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy. Radiology. 1997;204:467–470
  35. Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59:1127–1137
  36. Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100:366–375
  37. Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006;106:609–615

PII: S0167-8140(09)00497-6

doi: 10.1016/j.radonc.2009.08.045

Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 492-497 , December 2009

Article Tools

* Image Usage & Resolution